Is Protagonist Therapeutics, Inc. (PTGX) Overvalued?
We dive into why Protagonist Therapeutics, Inc. (PTGX) could be considered overvalued on 2026-07-24, based on AAII’s Value Score and Grade.Tudor Pop
Stock Evaluator: Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. PTGX
$136.64
-2.00
-1.44%
July 31, 2026 4:00:00 PM
EST
Volume: 548,760
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Commentary & Analysis
Which Is a Better Investment, CareDx, Inc. or Protagonist Therapeutics, Inc. Stock?
Learn more about whether CareDx, Inc. or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Protagonist Therapeutics, Inc.’s (PTGX) Stock Is Up 5.03%
As of Tuesday, July 07, Protagonist Therapeutics, Inc.’s PTGX share price has surged by 5.03%, which has investors questioning if this is right time to sell.Michael Rose
Which Is a Better Investment, Protagonist Therapeutics, Inc. or uniQure N.V. Stock?
Learn more about whether Protagonist Therapeutics, Inc. or uniQure N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Protagonist Therapeutics, Inc.’s (PTGX) Stock Is Up 5.51%
As of Thursday, June 04, Protagonist Therapeutics, Inc.’s PTGX share price has surged by 5.51%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | PTGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,928.3 | $251.9 | 76% |
|
| Shares Out (Mil) | 70.5 | 50.8 | 56% |
|
| Institutional Ownership | 99.4% | 92.0% | 88% |
|
| Float (Mil) | 52.5 | 40.5 | 48% |
|
| Beta | 1.83 | 0.95 | 89% |
|
| Avg Daily Volume (000s) | 528 | 447 | 60% |
|
| Price Change (52-week) |
152.4% | 54.2% | 96% |
|
| Growth | PTGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.0% | 14.0% | 58% |
|
| Net Income (5yr) | (14.5%) | (9.8%) | 26% |
|
| EPS (5yr) | (1.3%) | 16.3% | 29 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (27.5%) | (15.6%) | 22% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 12 | 11 | |
| Current EPS | $1.929 | $4.467 | ($0.188) | |
| Month Ago EPS | $1.772 | $4.173 | ($0.685) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $1.414 | $2.774 | ($0.434) | |
| Year/Year Chg | 3,758% | (317.9%) | (230.8%) | |
| Financials | PTGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $74 | $39 | 24% |
|
| Net Income (TTM) (Mil) | ($115) | ($43) | 10% |
|
| EPS (TTM) | ($1.789) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($117) | ($30) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $54 | $3 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $5 | 27% |
|
| Enterprise Value (Q1) (Mil) | $5,694 | $182 | 65% |
|
| Valuation | PTGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.60 | 2.60 | 93% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PTGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | (154.9%) | (64.7%) | 6% |
|
| ROA | (15.9%) | (49.7%) | 22% |
|
| ROE | (17.1%) | (55.4%) | 25% |
|
| Liabilities to Assets | 6.0% | 30.3% | 3% |
|
| F-Score | 3 | 3 | 19% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.6% |
| +/- S&P 500: | +14.1 |
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.8% |
| +/- S&P 500: | +15.3 |
